Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Hydrochloric acid

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Hydrochloric Acid (hcl) (opens in a new tab)Original source URL: https://globalrph.com/dilution/hydrochloric-acid-hcl/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/hydrochloric-acid-hcl/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:34.822001+00:00
Source location
div.post-content
Packaged content SHA-256
fba39ea073da01be30bc5037984a73566dcb06fe1e5ac3c5faf33a63cec9ba14
Original response SHA-256
75b3fcd1b7d90752cddd3ad29857b8969535b5e4222bb6b77d220d4f8eff8a49
Source body SHA-256
dcfa2a6161448921df6f8bc0f2cce4046fd77ac0ee917a948919be4c6c62d7a7

HYDROCHLORIC ACID (HCL)

Usual Diluents
D5W, NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
Preparation of 0.1 N solution
[100 ml (100 meq ) of 1.0N HCL] [1000 ml] [Infusion rate: see bottom section]
Filter HCL with 0.22 micron filter before adding it to the IV bag .

Alternatively (Using 37% HCL stock bottle):
[8.3 ml of 37% HCL] [1000 ml NS or D5W]

Preparation of 0.15 N solution
[150 ml (150 meq) of 1.0 N HCL] [1000 ml]

-This agent must be infused in glass or polyolefin container.
-Hydrochloric acid solution should be administered through a central venous line to prevent vein irritation, thrombophlebitis, or tissue necrosis. Do NOT infuse via a peripheral vein! Injection of HCl into a peripheral vein may cause extravasation and can produce severe tissue necrosis.
-Solutions for infusion should NOT exceed 0.2 N (increased risk of hemolysis and increased venous irritation). Concentrations >0.1 N have been reported to cause corrosive effects, even when administered through a central venous catheter.
-Serum electrolytes and blood gases should be measured every 4 hours.
-Solution should be filtered with a teflon 0.22 micron filter before adding to an IV bag. Sample filter: GE PTFE (Teflon®) Syringe Filters: Membrane compatible with most aggressive solutions. https://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&1051

Dosing:
H+ ion deficit (mEq) = 0.3 X weight (kg) X (measured HCO3 - desired HCO3 [mEq/L])
Rate of H+ replacement: 0.1 - 0.2 mEq/kg/hour
For example, 0.1 N solution IV at 100 mL/h provides about 10 mEq/h

Calculations:

Stock bottle of 37% HCL.
Determination of molarity of 37% HCL V/V
37 ml of solute/100 ml of solution.

HCL - 37% v/v. Specific gravity: 1.19 g/ml
37ml/100 ml or 370 ml/1000 ml x 1.19 g/ml = 440.3 g/L

HCL Molecular weight = 36.5
Molarity:
440.3 grams /36.5 grams = 12.06 M or ~12M

====================
Compounding 1 liter of 0.1N Solution
====================

M1V1 = M2V2
(0.1)(1000) = (12) (x)

x = (0.1) (1000) / 12
x = 8.3 ml

Therefore add 8.3 ml of 37% HCL to 1 liter of D5W or NS to create a 0.1N HCL solution.

---OR ---(Alternative calculation)

12M (37% HCL) = 12 moles/L = 12 x 36.5 = 438 g/L = 438 mg/ml.
Need 0.1 N = 0.1 M
0.1 M x 36.5 = 3.65 g/L = 3650 mg.

3650 mg / 438 mg = 8.33 ml*
Stability / Miscellaneous
Stability/storage: 24 hr (RT)

Indication: treatment of severe or refractory metabolic alkalosis. IV HCl may be indicated in severe metabolic alkalosis (pH >7.55) or when NaCl or KCl cannot be administered because of volume overload or advanced renal failure. May also be indicated if rapid correction of severe metabolic alkalosis is warranted (eg, cardiac arrhythmia or hepatic encephalopathy.)


Equations:

Base excess in blood (BE-B)
Base excess in blood (BE-B) is the number of mmol of strong acid that is needed to adjust to pH 7.4 a blood sample tested at pCO2 of 40 mm Hg and 37 C.It indicates the deviation in mmol/l of the buffer bases from the normal value.
BE - B = (1 - 0.014[Hb])([HCO3-] - 24 + (1.43[Hb] + 7.7)(pH - 7.4))
The BE requires the measurement of blood pH, hemoglobin, and HCO3.
H+ deficit (mEq) = 0.3 x Wt(kg) x ([HCO3-] - 35)
Rate of H+ replacement =0.1 to 0.2 meq/kg per hour.

Definitions:
The 'Normality' of a solution is the 'Molarity' multiplied by the number of equivalents per mole. The 'Molarity' of a solution is the number of moles of solute in one liter of solution. Source: https://www.uab.edu/clabsc/solution.htm

Source: DRUGDEX®:
Storage and Stability:
HYDROCHLORIC ACID (0.1N) is stable and compatible in VIAFLEX(R) PLASTIC CONTAINERS over a 24 hour storage period (Pers Comm, 1987).

Most studies recommend a 0.1 to 0.15 Normal hydrochloric acid solution prepared in sterile water, 5% dextrose in water or normal saline (Wagner et al, 1980g; Williams & Lyons, 1980g). One group of clinicians prepared a 0.1 Normal hydrochloric acid solution by drawing 100 milliequivalents of concentrated hydrochloric acid into a syringe and filtering it through a disposable 0.22 micron filter as it was added to a liter of 5% dextrose in water or normal saline (Wagner et al, 1980g). Others prepared a 0.15 Normal hydrochloric acid solution by diluting 12.5 milliliters of concentrated hydrochloric acid (35% to 38%) to a total volume of 1 liter with sterile water (Williams & Lyons, 1980g).

INTRAVENOUS RATE OF ADMINISTRATION: The rate of infusion was 100 to 125 milliliters/hour of a 0.15 Normal hydrochloric acid solution in sterile water (Williams & Lyons, 1980g). One group of practitioners infuses a liter of 0.1 Normal hydrochloric acid in 5% dextrose and water or normal saline over 4 to 6 hours (Wagner et al, 1980g). Some clinicians have corrected severe metabolic alkalosis with prolonged infusion of hydrochloric acid (over a period of 17 days), administering 100 to 400 milliequivalents hydrochloric acid daily through a central venous catheter as 0.1 Normal hydrochloric acid (Reisman & Puri, 1982f).

The amount of hydrochloric acid (HCL) administered is based upon base excess (milliequivalent/liter), with an equivalent amount being administered. One report recommends the following formula (Wagner et al, 1980g): HCL (mEq) = Weight (kilogram) x 0.3 X base excess (mEq/liter).

The amount of hydrochloric acid administered to each of the 21 patients treated was based upon 1 of 3 equations: Bicarbonate Excess = (0.5 X Weight in kg) X (serum bicarbonate -24); OR Chloride Deficit = (0.2 X Weight in kg) X (103- serum chloride); OR Base Excess = (0.3 X Weight in kg) X (measured base excess). The pH of amino acid solutions containing added hydrochloric acid was significantly higher than that observed with hydrochloric acid added to normal saline. The addition of 100 milliequivalent/liter hydrochloric acid to normal saline produced a pH of approximately 1.5, whereas, addition of the same amount to a 3.5%, 5.5%, and 8.5% amino acid solution increased the pH to approximately 3, 4.5, and 5, respectively.

The infusion generally continues until the total base excess is between 0 and 50 milliequivalent (Williams & Lyons, 1980g).
Source: UpToDate®:
Hydrochloric acid - If acetazolamide is ineffective, the metabolic alkalosis can be corrected directly by the intravenous infusion of HCl, which buffers the excess bicarbonate. HCl is usually given as an isotonic solution (150 meq per liter) over 8 to 24 h. It can be infused into a major vein (since HCl is very corrosive) or into a peripheral vein if the HCl is buffered in an amino acid solution and given with a fat emulsion.
The amount of HCl required (in meq) can be estimated from the space of distribution of bicarbonate in metabolic alkalosis (approximately equal to 50 percent of lean body weight [LBW] in kg) times the bicarbonate excess per liter:
HCO3 excess = 0.5 x LBW x (Plasma HCO3 - 24)
In a 60 kg woman with a plasma bicarbonate concentration of 38 meq/L, for example:
HCO3 excess = 0.5 x 60 x 14 = 420 meq
It is important to remember that this formula is only an estimate and that it does not take into account any continuing acid loss, as with nasogastric suction. Minimizing continuing acid loss in this setting with an H2-blocker also may be helpful.
Source: Merck Manual:
https://www.merck.com/mmpe/sec12/ch157/ch157d.html

Metabolic Alkalosis:
Underlying conditions are treated, with particular attention paid to correction of hypovolemia and hypokalemia.

Patients with Cl-responsive metabolic alkalosis are given 0.9% saline solution IV; infusion rate is typically 50 to 100 mL/h greater than urinary and other sensible and insensible fluid losses until urinary Cl rises to > 25 mEq/L and urinary pH normalizes after an initial rise from bicarbonaturia. Patients with Cl-unresponsive metabolic alkalosis rarely benefit from rehydration.

Patients with severe metabolic alkalosis (eg, pH > 7.6) sometimes require more urgent correction of serum pH. Hemofiltration or hemodialysis is an option, particularly if volume overload is present. Acetazolamide 250 to 375 mg po or IV once/day or bid increases HCO3 − excretion but may also accelerate urinary losses of K+ and PO4 −; volume-overloaded patients with diuretic-induced metabolic alkalosis and those with posthypercapnic metabolic alkalosis may especially benefit.

Hydrochloric acid in a 0.1 to 0.2 normal solution IV is safe and effective but must be given through a central catheter because it is hyperosmotic and scleroses peripheral veins. Dose is 0.1 to 0.2 mmol/kg/h, with frequent monitoring of ABG and electrolytes.
Alternatives (usage depends on patient specific conditions):
- Ammonium chloride (NH4Cl) (Note: Hydrochloric acid is the drug of choice in patients with hepatic dysfunction who are unable to tolerate ammonium chloride.)
CLINICAL PHARMACOLOGY: The ammonium ion (NH4+) in the body plays an important role in the maintenance of acid-base balance. The kidney uses ammonium (NH4+) in place of sodium (Na+) to combine with fixed anions in maintaining acid-base balance, especially as a homeostatic compensatory mechanism in metabolic acidosis. When a loss of hydrogen ions (H+) occurs and serum chloride (Cl−) decreases, sodium is made available for combination with bicarbonate (HCO3−). This creates an excess of sodium bicarbonate (NaHCO3) which leads to a rise in blood pH and a state of metabolic alkalosis.

The therapeutic effects of ammonium chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver, thereby liberating hydrogen (H+) and chloride (Cl−) ions into the extracellular fluid.

Dosing: Ammonium Chloride Injection, USP is administered intravenously and must be diluted before use. Solutions for intravenous infusion should not exceed a concentration of 1% to 2% of ammonium chloride. Dosage is dependent upon the condition and tolerance of the patient. It is recommended that the contents of one to two vials (100 to 200 mEq) be added to 500 or 1000 mL of isotonic (0.9%) sodium chloride injection. The rate of intravenous infusion should not exceed 5 mL per minute in adults (approximately 3 hours for infusion of 1000 mL). Dosage should be monitored by repeated serum bicarbonate determinations.
Supplied:
100 mEq (5 mEq/mL) - 20 ml vial
267.5 mg/ml.

For the treatment of hypochloremia or hypochloremic metabolic alkalosis in patients who cannot receive sodium chloride and who do not have end-stage hepatic disease: Intravenous dosage: Adults: Individualize dosage based on the patient's carbon dioxide combining power. Each gram of ammonium chloride will reduce the carbon dioxide combining power of a 70-kg adult by about 1.1 volume %, or 16 mg/kg will lower the carbon dioxide combining power by 1 volume %. In the absence of edema or hyponatremia, the dosage may be calculated on the basis of the chloride deficit by the following formula: mEq of chloride ion (as ammonium chloride) = chloride deficit x 0.2 L/kg x weight (kg). The chloride deficit is 103 - serum Cl in mEq/L. One-half of the calculated value should be administered, the carbon dioxide combining power should be rechecked and the need for further treatment assessed. Do not exceed a concentration of 1-2% of ammonium chloride or an infusion rate greater than 5 ml/minute.
- Acetazolamide (Diamox): chloride-resistant metabolic alkalosis. Metabolic alkalosis (unlabeled use): I.V. 250 mg every 6 hours for 4 doses or 500 mg single dose; reassess need based upon acid-base status. Alternatively: 5-10 mg/kg/d PO/IV divided q6h. Carbonic anhydrase inhibitor that blocks HCO3 reabsorption in the proximal renal tubules.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      hydrochloric-acid
      Source IDH51-95016EDA43E2044B73E13F90
      Generic name
      Hydrochloric acid
      Source IDH51-4D02B1A388CA29CD3583084B
      Class
      Electrolytes and fluids
      Source IDH51-9A9756C27C24A3C0017AC184
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-C73C343B645E44C87CCC8788
      Primary uses
      1. Correction of the named fluid, electrolyte, acid-base, or oncotic abnormality under monitored conditions.
        Source IDH51-1EC6656CF97AE0742D022204
      Mechanism
      Supplies hydrogen and chloride ions for selected severe metabolic alkalosis treatment.
      Source IDH51-77AC7C4B15494228FB20CDC7
      Mechanism level
      drug_specific
      Source IDH51-1253A6B17B7FD5E477EC2A01
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-838B777714F7AE255323DDCD
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-F20D1A37F2999865D6164646
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-E67FBCC5E2E7B9094B621A80
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-A176CC8D3553BD0EAB0D76CC
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-49DFE4058D3129BB81C7FCFA
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-C55AA90806B6438076642334
      Legacy title
      Hydrochloric acid
      Source IDH51-2FDB8C9DD6EFE89085A5E28B
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-571777D5D59F5CEEE30D8E59
      Search text
      Hydrochloric acid Electrolytes and fluids Legacy GlobalRPh directory entry Correction of the named fluid, electrolyte, acid-base, or oncotic abnormality under monitored conditions. Supplies hydrogen and chloride ions for selected severe metabolic alkalosis treatment. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-0C55828EECB331C5B8A90B9F
      Official access mode
      none
      Source IDH51-8BF7B6D6CFB809D73FB6BE99
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-F7D8AF0795B74F9FF9E08549

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-B23C6ADE5BBAE7F1C0AEFBB7
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-AE56F31425DC609708449C18
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-7C00E308E234387145BCD72E

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-767845507F9F76B8F0E5B3EB

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-70D5F27A16E5B0E0C9A6DD92
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      hydrochloric-acid
      Source IDH51-DA2290FFE5D962494499230D
      Legacy title
      Hydrochloric acid
      Source IDH51-C4D8A6B7CFD0C9FCAA59FA6E
      Generic name
      Hydrochloric acid
      Source IDH51-4F8ACB80B3F2F872CB1F306B
      Class
      Electrolytes and fluids
      Source IDH51-EDA60D4D6908381A6C926D58
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-F77EE3DFB21CE53211ACA952
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-61CE102D7F476063A2873153
      Populations
      1. Population not yet normalized
        Source IDH51-8D8C97BC2353447D8DB70102
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-06198A629A266E74FF97C35E
      High alert
      false
      Source IDH51-EA0962686D709CBA1BA79AEB
      Hazardous
      false
      Source IDH51-CEB3B8393ABFAF7303BAF64A
      Status
      Legacy migration
      Source IDH51-95E51DF028C45087882F384B
      Version added
      Legacy
      Source IDH51-AD604DD2D1B8C55359EB83BA
      Sources
      LabelUrlKind
      Source IDH51-C61B18ADE2C841FE642E81CC
      GlobalRPh legacy IV dilution monograph
      Source IDH51-0AF33761C52A766A4953DA80
      		legacy:auto
      Source IDH51-5274211576E8D8E7903F0DEE
      		Legacy
      Source IDH51-FFD3998BCA19D939D9D13BFF
      Clinical release verification
      Audit version
      3.4
      Source IDH51-8847E87DB10F148A9E4533A3
      Audited on
      2026-08-30
      Source IDH51-239E87CC51BC15436A88AD01
      Level
      red
      Source IDH51-CA0D2C441B667CF4D0BC8D2F
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-119C580CA5415D7EDE2ED194
      Exact current label candidate
      false
      Source IDH51-AD40DBA362BE786156A01D44
      Reference url count
      0
      Source IDH51-AA2CDF99EF2370D8956142A0
      Broken reference count
      0
      Source IDH51-34CD7F77C08D892BEA466C7C
      Point of use confirmation required
      true
      Source IDH51-1AADC54EBDF5BB9D9ED06353
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-BD3415B95A0E8C369D006EB2

      Dosing source fields

      Id
      hydrochloric-acid
      Source IDH51-C4C8EE986415BAFFB52D8575
      Generic name
      Hydrochloric acid
      Source IDH51-97C478B7506F2DE0CAE5A88D
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-009BC19166D0F86B808C1DA2
      Package insert
      Query name
      Hydrochloric acid
      Source IDH51-4CA47B1A7A0BE1957372AD0F
      Product and route must match
      true
      Source IDH51-E9CC3353862C55A46B86F5D1
      Live current label enabled
      false
      Source IDH51-1B4FDAFD070FD00891EE0575
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-08B737D95C430B3F4A578374
      Direct official label access enabled
      true
      Source IDH51-18AACC713416FB1A15346EF0
      Outbound server request required
      false
      Source IDH51-3C6FBEBD497FF3EC66CEFD6A
      Local summary status
      not_bundled
      Source IDH51-F23E7F738BFA3B2EFB17378B
      Clinical review
      Locally normalized
      false
      Source IDH51-F1A382F0037A3CCBE72C236E
      Reviewed
      2026-08-29
      Source IDH51-C8FDD2BC4FCEAAE729787F2B
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-2A8583ABF0D7794A02EEF75D
      Clinical release verification
      Audit version
      3.4
      Source IDH51-F214EDFE2F141A63E52D67DD
      Audited on
      2026-08-30
      Source IDH51-BBDDC7A3B5F5E570723995E8
      Level
      red
      Source IDH51-C4F74B38DB40154FDA092328
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-2B16DA46010BE9DF9C18AE2F
      Exact current label candidate
      false
      Source IDH51-004DAD126D8A10DF9B2E1BD4
      Reference url count
      0
      Source IDH51-EC679118E0DE3F44BB0A1D31
      Broken reference count
      0
      Source IDH51-709CD6589705CEB45AF20C4B
      Point of use confirmation required
      true
      Source IDH51-A0CEB2364D65591AD717815E
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-9FD1E8F8C0EB7A58ACA94FE1
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      hydrochloric-acid
      Source IDH51-5E538C51251C5CAE5E11B32C
      Name
      Hydrochloric acid
      Source IDH51-488981FADF29E15E7839DBA5
      Therapeutic class
      Electrolytes and fluids
      Source IDH51-646D0B8E12CC54344365A96C
      Review version
      3.1
      Source IDH51-A2AA1AD772D5D887124D90D9
      Review date
      2026-08-30
      Source IDH51-4426A74DBEA576C16639CDAB
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-E8B8033EA86A0AE6E0E16561
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-F5BCB0261C4EBFDB4BD2471D
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-1531B093F7A209A916C9497A
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5555EEB835E5AF35FB87A5C2
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-87BB5A301A1B0AB743DF1CF1
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C953FF0F42A06FC70CB141E8
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2E687CF5C3266D6F98C42DFF
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-13B620DA2E135B3220DE1154
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B4FF8CE1659DE2752A685CA4
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2387B9188B25AB5E888F7EAA
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D295D23CD6860F62C60F0752
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7E41F058661C02645D3C3ECB
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-4A7CC28EF3606A4B3D413400
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-C4C2915187AC9C8620EFE155
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-D6B448C9CD5E77330087D5FC
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-0762E1EB7EFAA1BD4B52504B
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-97306627F81043B5FF1454FF
      Adult dosing range
      Primary
      not_found
      Source IDH51-20B57DB58ECE30C38EAA0818
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-8EB06981DD1753A0B09CD15F
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-0503E23A28E67C41CC52E790
      Infusion time
      Primary
      not_found
      Source IDH51-5C60B57ECF8B883AEB34B202
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-05E065CCC3AEB6F11ED18334
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-FEDF121B32B9D9EC38C449C4
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-13A7F05334E5AAA027F6C8B0
      Guide generation allowed
      false
      Source IDH51-151DB8B9B0CF59DE64D628E3
      Pediatric
      Applicability
      not_established
      Source IDH51-A1910F3127EC2CCD044700AC
      Guide generation allowed
      false
      Source IDH51-F1DF5A9AB27F8CEA18A213A7
      Neonatal
      Applicability
      not_established
      Source IDH51-D53BA517A3D747AE8A17FBA4
      Guide generation allowed
      false
      Source IDH51-5A27031DBBAF6592EF736EAA
      Route presence
      Structured dilution
      false
      Source IDH51-40A9C9C33B24C59DCEB3AC80
      Iv push
      false
      Source IDH51-E3D29A586E9B3FD5B05D6878
      Continuous infusion
      false
      Source IDH51-6ED332F0D8505E3AD3CB0DC5
      Pediatric source
      false
      Source IDH51-B727CF08AD4AC7AE82E40714
      Neonatal source
      false
      Source IDH51-96A2A100E2952BCD2A2ED9BA
      Legacy reference
      Status
      not_available
      Source IDH51-C0B39982207294A8EA3C7A75
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-945C4DF81F39DFF0F05C710F
      Source files
      1. catalog.json
        Source IDH51-3E3D9FBF91404C7A10375726
      2. dosing.json
        Source IDH51-CC37373C0FE4A1DBA27B1D24
      3. legacy-map.json
        Source IDH51-D196A2131B33E8292DC93C79
      4. review-queue.json
        Source IDH51-1076B048E12493D66B9747D1
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-D79F38F1270C8AF14939FCAE
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-DA2290FFE5D962494499230Dcatalog.json
      /records/123/id      		Historical; current review incomplete
      H51-C4D8A6B7CFD0C9FCAA59FA6Ecatalog.json
      /records/123/legacy_title      		Historical; current review incomplete
      H51-4F8ACB80B3F2F872CB1F306Bcatalog.json
      /records/123/generic_name      		Historical; current review incomplete
      H51-EDA60D4D6908381A6C926D58catalog.json
      /records/123/class      		Historical; current review incomplete
      H51-F77EE3DFB21CE53211ACA952catalog.json
      /records/123/subclass      		Historical; current review incomplete
      H51-61CE102D7F476063A2873153catalog.json
      /records/123/summary      		Historical; current review incomplete
      H51-767845507F9F76B8F0E5B3EBcatalog.json
      /records/123/warnings/0      		Historical; current review incomplete
      H51-70D5F27A16E5B0E0C9A6DD92catalog.json
      /records/123/stability_notes/0      		Historical; current review incomplete
      H51-8D8C97BC2353447D8DB70102catalog.json
      /records/123/populations/0      		Historical; current review incomplete
      H51-06198A629A266E74FF97C35Ecatalog.json
      /records/123/evidence_tier      		Historical; current review incomplete
      H51-EA0962686D709CBA1BA79AEBcatalog.json
      /records/123/high_alert      		Historical; current review incomplete
      H51-CEB3B8393ABFAF7303BAF64Acatalog.json
      /records/123/hazardous      		Historical; current review incomplete
      H51-95E51DF028C45087882F384Bcatalog.json
      /records/123/status      		Historical; current review incomplete
      H51-084822A593748B4AADA4E306catalog.json
      /records/123/reviewed      		Historical; current review incomplete
      H51-AD604DD2D1B8C55359EB83BAcatalog.json
      /records/123/version_added      		Historical; current review incomplete
      H51-C61B18ADE2C841FE642E81CCcatalog.json
      /records/123/sources/0      		Historical; current review incomplete
      H51-0AF33761C52A766A4953DA80catalog.json
      /records/123/sources/0/label      		Historical; current review incomplete
      H51-5274211576E8D8E7903F0DEEcatalog.json
      /records/123/sources/0/url      		Historical; current review incomplete
      H51-FFD3998BCA19D939D9D13BFFcatalog.json
      /records/123/sources/0/kind      		Historical; current review incomplete
      H51-8847E87DB10F148A9E4533A3catalog.json
      /records/123/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-239E87CC51BC15436A88AD01catalog.json
      /records/123/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-CA0D2C441B667CF4D0BC8D2Fcatalog.json
      /records/123/clinical_release_verification/level      		Historical; current review incomplete
      H51-119C580CA5415D7EDE2ED194catalog.json
      /records/123/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-AD40DBA362BE786156A01D44catalog.json
      /records/123/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-ECEFB15E9BC140A9496B999Bcatalog.json
      /records/123/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-4DFA25995DF7D232DD4B1A9Dcatalog.json
      /records/123/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-987CAF9C2023397EF47D9000catalog.json
      /records/123/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-AA2CDF99EF2370D8956142A0catalog.json
      /records/123/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-34CD7F77C08D892BEA466C7Ccatalog.json
      /records/123/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-1AADC54EBDF5BB9D9ED06353catalog.json
      /records/123/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-BD3415B95A0E8C369D006EB2catalog.json
      /records/123/clinical_release_verification/note      		Historical; current review incomplete
      H51-09144E745B80AAB8E65FED8Acatalog.json
      /records/123/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-C4C8EE986415BAFFB52D8575dosing.json
      /records/123/id      		Historical; current review incomplete
      H51-97C478B7506F2DE0CAE5A88Ddosing.json
      /records/123/generic_name      		Historical; current review incomplete
      H51-009BC19166D0F86B808C1DA2dosing.json
      /records/123/coverage_status      		Historical; current review incomplete
      H51-4CA47B1A7A0BE1957372AD0Fdosing.json
      /records/123/package_insert/query_name      		Historical; current review incomplete
      H51-0F626E7390FDE644E7BD23C1dosing.json
      /records/123/package_insert/preferred_setid      		Historical; current review incomplete
      H51-E9CC3353862C55A46B86F5D1dosing.json
      /records/123/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-1B4FDAFD070FD00891EE0575dosing.json
      /records/123/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-08B737D95C430B3F4A578374dosing.json
      /records/123/package_insert/source_priority      		Historical; current review incomplete
      H51-18AACC713416FB1A15346EF0dosing.json
      /records/123/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-3C6FBEBD497FF3EC66CEFD6Adosing.json
      /records/123/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-F23E7F738BFA3B2EFB17378Bdosing.json
      /records/123/package_insert/local_summary_status      		Historical; current review incomplete
      H51-B23C6ADE5BBAE7F1C0AEFBB7dosing.json
      /records/123/renal/classification      		Historical; current review incomplete
      H51-AE56F31425DC609708449C18dosing.json
      /records/123/renal/summary      		Historical; current review incomplete
      H51-7C00E308E234387145BCD72Edosing.json
      /records/123/renal/method_note      		Historical; current review incomplete
      H51-F1A382F0037A3CCBE72C236Edosing.json
      /records/123/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-C8FDD2BC4FCEAAE729787F2Bdosing.json
      /records/123/clinical_review/reviewed      		Historical; current review incomplete
      H51-2A8583ABF0D7794A02EEF75Ddosing.json
      /records/123/clinical_review/status      		Historical; current review incomplete
      H51-F214EDFE2F141A63E52D67DDdosing.json
      /records/123/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-BBDDC7A3B5F5E570723995E8dosing.json
      /records/123/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-C4F74B38DB40154FDA092328dosing.json
      /records/123/clinical_release_verification/level      		Historical; current review incomplete
      H51-2B16DA46010BE9DF9C18AE2Fdosing.json
      /records/123/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-004DAD126D8A10DF9B2E1BD4dosing.json
      /records/123/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-8DB2F1AAF56FB50CDC22EAAFdosing.json
      /records/123/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-450206A15FC363E6F628D825dosing.json
      /records/123/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-C51DE78D1963852D9B232986dosing.json
      /records/123/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-EC679118E0DE3F44BB0A1D31dosing.json
      /records/123/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-709CD6589705CEB45AF20C4Bdosing.json
      /records/123/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-A0CEB2364D65591AD717815Edosing.json
      /records/123/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-9FD1E8F8C0EB7A58ACA94FE1dosing.json
      /records/123/clinical_release_verification/note      		Historical; current review incomplete
      H51-95976541DD13BBEF0394C87Ddosing.json
      /records/123/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-95016EDA43E2044B73E13F90first-look-v5.1.json
      /records/123/id      		Historical; current review incomplete
      H51-4D02B1A388CA29CD3583084Bfirst-look-v5.1.json
      /records/123/generic_name      		Historical; current review incomplete
      H51-9A9756C27C24A3C0017AC184first-look-v5.1.json
      /records/123/class      		Historical; current review incomplete
      H51-C73C343B645E44C87CCC8788first-look-v5.1.json
      /records/123/subclass      		Historical; current review incomplete
      H51-1EC6656CF97AE0742D022204first-look-v5.1.json
      /records/123/primary_uses/0      		Historical; current review incomplete
      H51-77AC7C4B15494228FB20CDC7first-look-v5.1.json
      /records/123/mechanism      		Historical; current review incomplete
      H51-1253A6B17B7FD5E477EC2A01first-look-v5.1.json
      /records/123/mechanism_level      		Historical; current review incomplete
      H51-838B777714F7AE255323DDCDfirst-look-v5.1.json
      /records/123/basic_dosing_orientation      		Historical; current review incomplete
      H51-F20D1A37F2999865D6164646first-look-v5.1.json
      /records/123/administration_orientation      		Historical; current review incomplete
      H51-E67FBCC5E2E7B9094B621A80first-look-v5.1.json
      /records/123/renal_and_population_orientation      		Historical; current review incomplete
      H51-A176CC8D3553BD0EAB0D76CCfirst-look-v5.1.json
      /records/123/key_safety_orientation/0      		Historical; current review incomplete
      H51-49DFE4058D3129BB81C7FCFAfirst-look-v5.1.json
      /records/123/coverage_path      		Historical; current review incomplete
      H51-C55AA90806B6438076642334first-look-v5.1.json
      /records/123/coverage_path_label      		Historical; current review incomplete
      H51-432865F48BCDD963A0127432first-look-v5.1.json
      /records/123/official_label_url      		Historical; current review incomplete
      H51-2FDB8C9DD6EFE89085A5E28Bfirst-look-v5.1.json
      /records/123/legacy_title      		Historical; current review incomplete
      H51-571777D5D59F5CEEE30D8E59first-look-v5.1.json
      /records/123/review_note      		Historical; current review incomplete
      H51-0C55828EECB331C5B8A90B9Ffirst-look-v5.1.json
      /records/123/search_text      		Historical; current review incomplete
      H51-DFCD1714C00A773470CE6FA3first-look-v5.1.json
      /records/123/official_search_url      		Historical; current review incomplete
      H51-8BF7B6D6CFB809D73FB6BE99first-look-v5.1.json
      /records/123/official_access_mode      		Historical; current review incomplete
      H51-1834EF9A1E1ED4588DE62B42first-look-v5.1.json
      /records/123/official_access_url      		Historical; current review incomplete
      H51-76BEFE45C62D347A1947A8C6first-look-v5.1.json
      /records/123/official_search_query      		Historical; current review incomplete
      H51-F7D8AF0795B74F9FF9E08549first-look-v5.1.json
      /records/123/official_access_reason      		Historical; current review incomplete
      H51-5E538C51251C5CAE5E11B32Cpreparation-assessments-v3.8.json
      /123/id      		Historical; current review incomplete
      H51-488981FADF29E15E7839DBA5preparation-assessments-v3.8.json
      /123/name      		Historical; current review incomplete
      H51-4EF2CD89DA0CAD14A71F25EFpreparation-assessments-v3.8.json
      /123/brands      		Historical; current review incomplete
      H51-646D0B8E12CC54344365A96Cpreparation-assessments-v3.8.json
      /123/therapeutic_class      		Historical; current review incomplete
      H51-A2AA1AD772D5D887124D90D9preparation-assessments-v3.8.json
      /123/review_version      		Historical; current review incomplete
      H51-4426A74DBEA576C16639CDABpreparation-assessments-v3.8.json
      /123/review_date      		Historical; current review incomplete
      H51-E8B8033EA86A0AE6E0E16561preparation-assessments-v3.8.json
      /123/release_status      		Historical; current review incomplete
      H51-F5BCB0261C4EBFDB4BD2471Dpreparation-assessments-v3.8.json
      /123/market_status/status      		Historical; current review incomplete
      H51-1531B093F7A209A916C9497Apreparation-assessments-v3.8.json
      /123/market_status/basis      		Historical; current review incomplete
      H51-5555EEB835E5AF35FB87A5C2preparation-assessments-v3.8.json
      /123/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-87BB5A301A1B0AB743DF1CF1preparation-assessments-v3.8.json
      /123/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-C953FF0F42A06FC70CB141E8preparation-assessments-v3.8.json
      /123/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-2E687CF5C3266D6F98C42DFFpreparation-assessments-v3.8.json
      /123/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-13B620DA2E135B3220DE1154preparation-assessments-v3.8.json
      /123/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-B4FF8CE1659DE2752A685CA4preparation-assessments-v3.8.json
      /123/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-2387B9188B25AB5E888F7EAApreparation-assessments-v3.8.json
      /123/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-D295D23CD6860F62C60F0752preparation-assessments-v3.8.json
      /123/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-7E41F058661C02645D3C3ECBpreparation-assessments-v3.8.json
      /123/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-E3AD4C36E5C8161B82EE334Apreparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-CB78614CE0DDED04B486FDE0preparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-183BA5265A426F02979B2D7Fpreparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-25D2C460FA78817DBACA62B7preparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-4A7CC28EF3606A4B3D413400preparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-8314578878FF3A2C25F27179preparation-assessments-v3.8.json
      /123/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-C4C2915187AC9C8620EFE155preparation-assessments-v3.8.json
      /123/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-D6B448C9CD5E77330087D5FCpreparation-assessments-v3.8.json
      /123/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-0762E1EB7EFAA1BD4B52504Bpreparation-assessments-v3.8.json
      /123/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-97306627F81043B5FF1454FFpreparation-assessments-v3.8.json
      /123/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-20B57DB58ECE30C38EAA0818preparation-assessments-v3.8.json
      /123/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-8EB06981DD1753A0B09CD15Fpreparation-assessments-v3.8.json
      /123/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-0503E23A28E67C41CC52E790preparation-assessments-v3.8.json
      /123/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-5C60B57ECF8B883AEB34B202preparation-assessments-v3.8.json
      /123/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-05E065CCC3AEB6F11ED18334preparation-assessments-v3.8.json
      /123/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-FEDF121B32B9D9EC38C449C4preparation-assessments-v3.8.json
      /123/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-13A7F05334E5AAA027F6C8B0preparation-assessments-v3.8.json
      /123/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-151DB8B9B0CF59DE64D628E3preparation-assessments-v3.8.json
      /123/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-A1910F3127EC2CCD044700ACpreparation-assessments-v3.8.json
      /123/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-F1DF5A9AB27F8CEA18A213A7preparation-assessments-v3.8.json
      /123/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-D53BA517A3D747AE8A17FBA4preparation-assessments-v3.8.json
      /123/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-5A27031DBBAF6592EF736EAApreparation-assessments-v3.8.json
      /123/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-40A9C9C33B24C59DCEB3AC80preparation-assessments-v3.8.json
      /123/route_presence/structured_dilution      		Historical; current review incomplete
      H51-E3D29A586E9B3FD5B05D6878preparation-assessments-v3.8.json
      /123/route_presence/iv_push      		Historical; current review incomplete
      H51-6ED332F0D8505E3AD3CB0DC5preparation-assessments-v3.8.json
      /123/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-B727CF08AD4AC7AE82E40714preparation-assessments-v3.8.json
      /123/route_presence/pediatric_source      		Historical; current review incomplete
      H51-96A2A100E2952BCD2A2ED9BApreparation-assessments-v3.8.json
      /123/route_presence/neonatal_source      		Historical; current review incomplete
      H51-C0B39982207294A8EA3C7A75preparation-assessments-v3.8.json
      /123/legacy_reference/status      		Historical; current review incomplete
      H51-945C4DF81F39DFF0F05C710Fpreparation-assessments-v3.8.json
      /123/label_resolution/status      		Historical; current review incomplete
      H51-3E3D9FBF91404C7A10375726preparation-assessments-v3.8.json
      /123/source_files/0      		Historical; current review incomplete
      H51-CC37373C0FE4A1DBA27B1D24preparation-assessments-v3.8.json
      /123/source_files/1      		Historical; current review incomplete
      H51-D196A2131B33E8292DC93C79preparation-assessments-v3.8.json
      /123/source_files/2      		Historical; current review incomplete
      H51-1076B048E12493D66B9747D1preparation-assessments-v3.8.json
      /123/source_files/3      		Historical; current review incomplete
      H51-D79F38F1270C8AF14939FCAEpreparation-assessments-v3.8.json
      /123/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top